中国药理学与毒理学杂志2024，Vol.38Issue(4)：304-313,10.DOI:10.3867/j.issn.1000-3002.2024.04.008
产气荚膜梭菌致病机制及其治疗性抗体研究进展
Research progress in pathogenic mechanisms and therapeutic antibodies of Clostridium perfringens
摘要
Abstract
Clostridium perfringens(CP)is a common zoonotic pathogen that widely exists in nature and takes a heavy toll on human health and animal husbandry through its secreted exotoxins.The main pathogenic toxins of CP are α,β,ε and τ toxins,enterotoxins and necrotizing enteritis B-like toxins.The diseases caused by these toxins vary.Antibiotic therapy is currently the main method for the treat-ment of CP infection,but due to the growing drug resistance,it is increasingly difficult to control CP infection.In recent years,based on the rapid development of genetic engineering technologies,vaccines or antibodies against different exotoxins may become a new generation of immunotherapy for CP infec-tion.Studies have shown that the vaccines against CP α-toxin can prevent type A CP infection in mice.Anti-α-toxin single chain antibodies,bivalent single chain antibodies and nano-antibody can specifically bind to α-toxin,effectively neutralize the phospholipase C activity of α-toxin,and protect mice against lethal doses of α-toxin challenge.This article reviews the main pathogenic factors and mechanisms of CP and the research progress in genetic engineering antibody therapies so as to provide reference for the prevention and treatment of CP infection.关键词
产气荚膜梭菌/毒素/抗体Key words
Clostridium perfringens/toxin/antibody分类
医药卫生引用本文复制引用
赵品楠,罗龙龙..产气荚膜梭菌致病机制及其治疗性抗体研究进展[J].中国药理学与毒理学杂志,2024,38(4):304-313,10.基金项目
国家自然科学基金(82204262) （82204262）
北京市科技新星人才项目(Z211100002121020) （Z211100002121020）
北京市科技新星交叉课题(20220484216) National Natural Science Foundation of China(82204262) （20220484216）
Beijing Science and Technology New Star Talent Project(Z211100002121020) （Z211100002121020）
and Beijing Science and Technology New Star Cross Project(20220484216) （20220484216）
